English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech (Sci&Research)
Asia-Pacific has Record Year for Clinical Trials says Novotech CRO
Jan 21, 2020 10:40 HKT
中國抗體榮獲「最受投資者歡迎新股公司」大獎
Jan 10, 2020 12:19 HKT
SinoMab Granted the "Most Popular Newly Listed Company" Award
Jan 10, 2020 12:18 HKT
Tauriga Sciences, Inc. Approved by Alibaba Group to Operate Global Seller Account
Jan 07, 2020 08:00 HKT
Tauriga Sciences, Inc. Approved by Alibaba Group to Operate Global Seller Account
Jan 07, 2020 08:00 HKT
新年喜訊第一彈!東曜藥業(1875.HK)生物藥研發獲納入國家「重大新藥創制」科技重大專項
Jan 02, 2020 18:12 HKT
TOT BIOPHARM Biological Drug R&D Project Makes List of National Major Scientific and Technological Special Projects for "Significant New Drug Development"
Jan 02, 2020 18:11 HKT
維亞生物獲納入恒生香港上市生物科技指數
Dec 19, 2019 08:41 HKT
Viva Biotech Was Included as a Constituent Stock of the Hang Seng Hong Kong-Listed Biotech Index
Dec 19, 2019 08:40 HKT
東曜藥業獲納入「蘇州工業園區2019年度上市獎勵企業」名單
Dec 16, 2019 08:31 HKT
TOT BIOPHARM Included in the "Suzhou Industrial Park - 2019 Awarded Listed Enterprises"
Dec 16, 2019 08:30 HKT
Holista Files Patent for Water-Soluble Technology Targeting Cannabidiol (CBD) and Other High-Value, Fat-Soluble Nutraceuticals
Dec 12, 2019 12:00 HKT
Join Asia's Pharma & Biotech Festival in Singapore
Dec 09, 2019 08:08 HKT
中国生物制药公布2019年第三季度业绩
Nov 26, 2019 19:53 HKT
中國生物製藥公佈2019年第三季度業績
Nov 26, 2019 19:51 HKT
Sino Biopharmaceutical Announces 2019 Third Quarterly Results
Nov 26, 2019 19:50 HKT
类风湿关节炎治疗市场蓝海潜力巨大 中国抗体公布在研药物SM03类风湿关节炎III期临床试验最新进展
Nov 20, 2019 16:37 HKT
類風濕關節炎治療市場藍海潛力巨大 中國抗體公佈在研藥物SM03類風濕關節炎III期臨床試驗最新進展
Nov 20, 2019 16:35 HKT
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA
Nov 20, 2019 16:34 HKT
Global BioLife to Present 3F Antimicrobial Fragrance at 2020 ASM Biothreats
Nov 15, 2019 02:00 HKT
Next >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: